CPHI WORLDWIDE 2017

24 – 26 October 2017

Messe Frankfurt, Germany

THE WORLD’S LEADING PHARMACEUTICAL PLATFORM

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 42,000 visiting pharma professionals over three days. 2,500+ exhibitors from 153 countries gather at the event to network and take advantage of more than 150 free industry seminars. Every sector of the pharmaceutical market is represented under one roof, this year in Frankfurt. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.

The exhibition showcases cover the whole spectrum of pharmaceutical manufacturing and ingredients sourcing, offering products and services that cover the entire supply chain.

  • ‍PhI Worldwide: for pharmaceutical ingredients
  • ICSE: for outsourcing solution providers, contract manufacturing and services
  • InnoPack: for pharmaceutical packaging and drug delivery systems
  • P-MEC: for pharmaceutical machinery, technology and equipment
  • Finished Dosage Formulation (FDF): for every aspect of the finished dosage supply chain
Frankfurt CPhI 2017

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.